

# Evaluation of the fungi detection capability of Microsart<sup>®</sup> ATMP Fungi and Microsart<sup>®</sup> ATMP Sterile Release

Product Identifier	
Version number	1
Release date	06.12.2019
Document Identifier	
Version number	1
ID#	VA07.01EN
Release date	06.12.2019
Changes from last version	n.a.
Distribution	QM, R&D, Marketing

Approval				
Test Facility 1	Minerva Biolabs GmbH, Schkopauer Ring 13, 12861	Berlin, German	у	
Written by:	Dr. Denis Ciato Head of Product Development	- Date:	06.12.2019	
Reviewed by:	Matthias Hornschuh Scientist	Date:	06.12.2019	
Reviewed by:	Dr. Dirk Vollenbroich Managing Director	Date:	06.12.2019	
Test Facility 2	Sartorius Stedim Biotech GmbH, August-Spindler-Strasse 11, 37079 Goettingen, Germany			
Reviewed by:	Dr. Diana Patzelt/Dr. Alexandra Mueller-Scholz Scientist Applications for Molecular Biology	Date:	OR. 12.2019	
Reviewed by:	Kai Nesemanh Product Manager	- Date:	2.12.2019	
Reviewed by:	Gerhard Hanke Gerhard Haake/Anna Vreemann Quality Assurance Microbiology	- Date:	2020-01-08	

# Table of Contents

1	Introduction	1-3
2	Objective	2-4
3	Definitions and Abbreviations	3-5
4	Responsibilities	4-6
5	Test Material	5-7
	5.1 Test System	5-7
	5.2 Sample Matrix	5-7
	5.3 Microorganisms and ATMP samples for sensitivity, specificity and robustness tes	ting 5-8
	5.4 Incoming goods inspection and qualification of native material	5-9
	5.5 Compendial culture method	5-10
~	5.6 Equipment	5-10
6	Test Procedure	6-13
	6.1 Sample preparation	6-13
	6.2 Analytical procedures	6-13 6 4 5
	6.3 System suitability test criteria	6 15
	6.5 Calculations	6-15
	6.6 Reporting requirements	6-16
	6.7 Overview of experimental settings	6-16
	6.7.1 LOD <sub>05</sub> determination / Fundi Detection Range	6-16
	6.7.2 PCR specificity	6-18
	6.7.3 Comparison of Microsart <sup>®</sup> ATMP Fundi with compendial sterility test	6-18
	6.7.4 Robustness	6-18
7	Study Results	7-20
'	7.1 LOD <sub>05</sub> Detection Limit	7-20
	7.2 Specificity	7-23
	7.2.1 Sequence Alignment	7-23
	7.2.2 Fungi Detection Range	7-24
	7.2.3 Sample Matrix effects / Cross reactivity	7-25
	7.2.4 Specificity of PCR with genomic DNA	7-25
	7.2.5 Comparison of Microsart <sup>®</sup> ATMP Fungi with the compendial culture method	Fehler!
Te	xtmarke nicht definiert.	1 0111011
	7.3 Robustness	7-27
	7.3.1 Cell culture samples spiked with fungi	7-27
	7.3.2 Device compatibility	7-28
	7.3.2 Detection of Free-DNA	7-31
	7.3.3 False positive rate	7-32
8	Conclusion	8-34
9	Reference Documents	9-35
10		

## 1 Introduction

Gene therapy, somatic cell therapy and engineered tissue products are classified as so called Advanced Therapy Medicinal Products (ATMPs). In contrast to parenteral drug products, microbial safety at time of lot release cannot be guaranteed for the majority of ATMP products. Typical shelflives of less than 48 hours are in contrast to the current compendial microbiological control test which takes 7 to 14 days before a contamination can be ruled out with certainty. For ATMPs, microbial safety cannot be guaranteed at time of admission. These facts explain the high demand for growth-independent rapid ATMP testing. In order to enhance sensitivity and duration of microbial detection control tests, a more rapid method using real time PCR has been developed by the cooperation partners Minerva Biolabs and Sartorius Stedim Biotech. Following the development of Microsart® ATMP Mycoplasma and Microsart® ATMP Bacteria, this study has been conducted in order to validate the kits Microsart® ATMP Fungi as well as the fungi SR mix from Microsart® Sterile Release used for the detection of fungi contamination in ATMPs. Microsart® ATMP Fungi as well as Fungi SR Mix include a mix of primer, nucleotides and polymerase containing a FAM<sup>™</sup> labeled probe specific for a broad range of different fungi genera. False negative results due to PCR inhibitors or improper DNA extraction are detected by the internal amplification control. The internal amplification control can be added to the sample prior to DNA extraction and analysis for verification of the complete process (DNA extraction and PCR reaction). The internal amplification control can also be added directly to the PCR master mix to act as a PCR control only. The amplification of the control reaction is detected at 610 nm (ROX<sup>™</sup> channel) and the fungi specific sequence at 520 nm (FAM<sup>™</sup> channel).

Sartorius stedim	Product Validation Report Microsart <sup>®</sup> ATMP Fungi/Microsart® ATMP Sterile Release	Dated: 04.12.2019 Document Version: 1 Document ID: VA07.01EN Page 4 of 40
------------------	---	--

# 2 Objective

A study was designed to evaluate the fungal detection capability for the fungal control detection system Microsart<sup>®</sup> ATMP Fungi and the fungi SR mix of its derivate product Microsart<sup>®</sup> ATMP Sterile Release, for qPCR. A number of guidance documents are published to demonstrate that rapid and alternative microbiological methods are suitable for their intended use. These include the Parenteral Drug Association (PDA) Technical Report 33, European Pharmacopoeia (Ph. Eur.) chapter 5.1.6 and United States Pharmacopoeia (USP) chapter <1223>. This comprehensive validation plan is intended to show suitability of the new product, Microsart<sup>®</sup> ATMP Fungi and Microsart<sup>®</sup> ATMP Sterile Release, for fungi control testing in ATMPs. The validation study was setup to fulfill Ph. Eur. chapter 5.1.6. Part 4-1-1, *Primary validation to be performed by the supplier*. All parameters were validated with characteristic and most challenging test setups. Furthermore, comparability to the compendial method was demonstrated. Selected spiked samples of the sensitivity testing (chapter 7.2) was tested in parallel at an external contract lab according to Ph. Eur. 2.6.1. In this validation at least one lot has been tested. At least two additional lots have been tested for functionality during a separate shelf-life study.

# **3** Definitions and Abbreviations

ATMP	Advanced Therapy Medicinal Product
CFU/ml	Colony-forming Units per milliliter
DMEM	Dulbecco's modified Eagles medium
DNA	deoxyribonucleic acid
EP/ Ph. Eur.	European Pharmacopoeia
FBS	Fetal Bovine Serum
GC/ml	genome copies per milliliter
L+S	Labor LS SE & Co. KG
	Mangelsfeld 4, 5, 6
	97 708 Bad Bocklet
	Deutschland
LOD	limit of detection
MB	Minerva Biolabs GmbH
N/A	not applicable
NEC	negative extraction control
nm	nanometer
NTC	no template control
PC	positive control
PCR	polymerase chain reaction
PDA	Parenteral Drug Association
QC	Quality Control
SSB	Sartorius Stedim Biotech GmbH

## 4 Responsibilities

Minerva Biolabs GmbH (MB) was responsible for developing the test protocol in agreement with Sartorius Stedim Biotech GmbH (SSB). SSB was responsible for reviewing the test protocol to ensure its accuracy, completeness and validity.

Test initiation was scheduled by MB and SSB after approval of the validation plan by signing and exchanging a copy of the plan cover page and the necessary material for testing have been exchanged and received.

SSB and MB technicians executed the test protocol. MB and SSB were responsible for the execution of dedicated parts of the protocol.

MB drafted the validation report and SSB reviewed and approved the document to ensure its validity. The report was closed by exchanging a signed copy of the report cover page.

Deviations, including test failures and protocol modifications which occurred during the execution of the test protocol had been discussed between MB and SSB.

# 5 Test Material

The tests were conducted using the following test system, product solutions and material.

### 5.1 Test System

The test system used for the detection of fungi during this study was as follows:

	Table 1.	Test System	Information
--	----------	-------------	-------------

System type	Catalogue No.	Supplied by	Storage Conditions	Lot No.
Microsart <sup>®</sup> ATMP Fungi (100 tests)	SMB95-1012	SSB/MB	+2 – +8 °C	9519S1049 9519S1069 9519S1099
Fungi SR mix of Microsart <sup>®</sup> ATMP Sterile Release (10 samples)	SMB95-1007	SSB/MB	+2 – +8 °C	9518S1109
Microsart <sup>®</sup> ATMP Extraction (50 tests)	SMB95-2001	SSB/MB	Ambient Temperature	95261058 9526L1058 9526U1078 9526S1059 9526S1079

### 5.2 Sample Matrix

Sample matrix, with defined cell culture medium components (Table 2), were used for specificity testing, LOD (Limit of Detection) determination and robustness testing. For sensitivity testing, a panel of ten different fungal species (Table 3) were diluted in DMEM + 5% FBS to prepare dilution series. Furthermore to demonstrate specificity and robustness, at least four different cell culture samples with different culture media compositions were spiked with 99 CFU/ml of one of the fungal species which was detected with the highest LOD<sub>95</sub> value during LOD<sub>95</sub> determination (selected from the two EP 2.6.1/EP 2.6.27 fungi listed Table 12).

All matrices have been heat-treated for 20 min at 95 °C to inactivate all containing DNases. The heat-treated suspensions were stored  $\leq$  -18 °C and intensively vortexed after thawing for immediate use.

Product Ingredient	Manufacturer/Source	Catalogue No.	Lot No.	Storage Conditions
ChondroMAX Differentiation Medium	Sigma Aldrich	SCM123-100ml	SLBT3800	≤ -18 °C
Chrondrocyte Differentiation Medium	Sigma Aldrich	411D-250	745	+2 - +8 °C
DMEM, high glucose, GlutaMAX™ Supplement	Gibco/Thermo Fisher	10566016	2085084	+2 - +8 °C
DMEM liquid medium with stable Gtutamine	Merck/Biochrom AG	FG 0415	0731E 0147G	+2 - +8 °C
DMEM liquid medium w/o Na- Pyruvate, with stable Glutamine	Merck/Biochrom AG	FG0435	1014F	+2 - +8 °C
DMEM/F-12, GlutaMAX™ Supplement	Gibco/Thermo Fisher	10565018	1930078	+2 - +8 °C
FBS	Biochrom AG-	S0615-	0167F	≤ -18 °C

Table 2. Matrix Components

MB minerva biolabs* sartorius stedim	Product Validation Report Microsart <sup>®</sup> ATMP Fungi/Microsart® ATMP Sterile Release Dated: 04.12.2019 Document Version: 1 Document ID: VA07.01EN Page 8 of 40					
	Gibco/Thermo Fisher	1070106	S0615 0973F- 42Q0685	к		
GlutaMAX Supplement	Gibco/Thermo Fisher	35050061	2059587	2°C to 8°C		
Human Osteoblast Differentiation Medium	Sigma Aldrich	417D-250	715	+2 - +8 °C		
Human Serum	Sigma Aldrich	H6914-100ML	SLBT287	3 +2 - +8 °C		
KnockOut DMEM	Gibco/Thermo Fisher	10829018	2026761	+2 - +8 °C		
Leibovitz's L-15 Medium	Gibco/Thermo Fisher	11415064	2060481	+2 - +8 °C		
LymphoONE™ T-Cell Expansion Xeno-Free Medium	Takara	WK552S	AJ3P037	+2 - +8 °C		
McCoys 5A Medium	Gibco/Thermo Fisher	16600082	2085107	+2 - +8 °C		
МЕМ	Sigma Aldrich	M8167-500ml M4655-500ml	RNBG16 RNBG544	17 +2 - +8 °C 41		
Opti-MEM™ I Reduced Serum Medium, GlutaMAX™ Supplement	Gibco/Thermo Fisher	51985026	1929010	+2 - +8 °C		
Penicillin-Streptomycin (10,000 U/mL)	Gibco/thermos Fisher	15140122	2041561	MK -5°C to -20°C		
RPMI 1640 Medium (ATCC modification)	Gibco/Thermo Fisher	A1049101	2085378	+2 - +8 °C		
RPMI 1640 Medium, no glutamine no phenol red	Gibco/Thermo Fisher	3240414	2063458	+2 - +8 °C		

Dated: 04.12.2019

#### 5.3 Microorganisms and ATMP samples for sensitivity, specificity and robustness testing

For sensitivity, specificity and robustness testing, 12 different microorganisms were used, selected among the most common contaminants (Table 3).

For CFU-based tests, 7 quantified microorganisms with a defined cell count were used. These microorganisms are listed in table 3.

Another 6 microorganisms were tested at DNA-level using lyophilized DNA preparations containing genomic DNA of the particular species (Table 3) provided by MB. Fungi and bacteria were cultivated under ATCC® described conditions followed by DNA extraction, quantification and lyophilisation. Briefly, 5-10 ml are inoculated with the respective species and incubated overnight. A main culture of 50-100 ml is inoculated from the overnight culture and incubated, before harvest at the end of the logarithmic phase. Microorganisms are harvested by centrifugation at 4000 x g at 4-8 °C and genomic DNA is extracted via column purification.

Extracted DNA is analyzed using standardized methods in the following order:

- a. partial sequencing and Nanodrop measurement
- b. OD ratios between  $OD_{260/280} = 1.8-2.0$  and  $OD_{260/230} > 1.5$  are allowed for further analysis
- c. DNA concentration of intact DNA is subsequently determined via Qubit
- d. Qubit based concentrations are used for genome copy number determination.

#### Table 3. Microorganisms tested

Species	Strain	Supplier	Lot-No.	Catalogue-No.	Assay
Species used for CFU-based analys					
Candida albicans <sup>a, b</sup>	ATCC 10231	Microbiologics	443-810	443	Table 12, assay 1 Table 14, assay 9 Table 16, assay 1 Table 17, Assay 2
Candida tropicalis	ATCC 750	Minerva Biolabs	-	-	Table 13, Assay 3
Candida krusei	ATCC 6258	Minerva Biolabs	-	-	Table 13, Assay 5 Table 14, Assay 10
Candida glabrata	ATCC 90030	Minerva Biolabs	-	-	Table 13, Assay 4
Aspergillus brasilliensis <sup>a, b</sup>	ATCC 16404	Microbiologics	392-778-2	392	Table 12, Assay 2 Table 14, Assay 8 Table 16, assay 2 Table 17, Assay 1 Table 17, Assay 2
Aspergillus fumigatus	ATCC 9197	Minerva Biolabs	-	-	Table 13, Assay 6
Penicillium chrysogenum	ATCC 9178	Minerva Biolabs	-	-	Table 13, Assay 7
Species used for DNA-based analys	sis				
Candida guilliermondii		Minerva Biolabs	2104119471065	210411947	Table 15, Assay 1
Candida albicans		Minerva Biolabs	5113861108	51-1386	Table 15, Assay 1 Table 17, Assay 3 Table 17, Assay 4
Candida haemulonii		Minerva Biolabs	2105706241065	210570624	Table 15, Assay 1
Bacillus subtilis	ATCC 6633	Minerva Biolabs	5100101107	51-0010	Table 15, Assay 2
Pseudomonas aeruginosa	ATCC 10145	Minerva Biolabs	5200711049	52-0071	Table 15, Assay 2
Legionella pneumophila	ATCC 33152	Minerva Biolabs	5201011079	52-0101	Table 15, Assay 2

<sup>a</sup>EP 2.6.1 listed fungal strains

<sup>b</sup>EP 2.6.27 listed fungal strains

Cell samples for specificity and robustness testing consist of four different cell culture samples representing a broad spectrum of host species and applications (Table 4). Cell lines are cultivated according to ATCC<sup>®</sup> sub culturing guidelines. Cell counts and flask numbers are increased by passaging till reaching the required amount of cells. At the final passage cells are harvested and counted, followed by low speed sedimentation at 950 x g and resuspension in medium.

Cell Type	Origin/ATCC	Species	Media Composition
HeLa	Cervix, epithelial, ATCC <sup>®</sup> CCL-2 <sup>™</sup>	H. sapiens	DMEM, 5% FBS
Vero	Kidney, epithelial, ATCC <sup>®</sup> CCL-81 <sup>™</sup>	C. aethiops	DMEM, 5% FBS
СНО-К1	Ovary, epithelial-like, ATCC <sup>®</sup> CCL-61 <sup>™</sup>	C. griseus	DMEM, 5% FBS
Human Peripheral Blood Mononuclear Cells	Primary cells Lonza CC-2702	H. sapiens	Tahara lympho one Medium + 5 % HS
Jurkat	T-cell, DSM ACC 282	H.sapiens	RPMI, penicillin/Streptomycin, Glutamax, 5% FBS

<u>Table 4.</u> Description of cell samples used as background for spiking experiments

### 5.4 Incoming goods inspection and qualification of native material

EZ-CFU from Microbiologics and native material from Minerva Biolabs GmbH of species listed in Table 6 were tested in an incoming good inspection to determine or confirm the cell count.

1. Two pellets of EZ-CFU were rehydrated in 2 ml of rehydration buffer and diluted in a 1:10 dilution step in a standard phosphate buffer pH 7.2. At least three agar plates (Sabouraud agar) were inoculated with 100 μL, incubated for 24-48h and checked for colony formation.

Cell counts of all EZ-CFU were confirmed to be in the range of 10-100 CFU. Consequently all EZ-CFU fulfill the manufacturer's specification and are accepted for validation.

2. 50-100 ml of Sabouraud medium are spiked with few microliter of a concentrated solution of the species of interest. Culture is performed with shaking at the recommended temperature (Table 6). After 24-48h the solution is aliquoted with Glycerol and freeze down. The next day, one aliquots is diluted in a 1:10 dilution step in a standard phosphate buffer pH 7.2. At least three agar plates (Sabouraud agar) were inoculated with 100 μL, incubated for 24-48h and checked for colony formation.

The incubation conditions for each microorganism are listed in Table 6.

Table 5. Fungi Cultivation Media Ingredients

Medium	Manufacturer	Catalog No.	Lot No.
Dextrose	SIGMA	D9434-250G	SLBT1203
Mycological peptone	SIGMA	777199-500G	BCBR2356V
Sabouraud +4% Dextrose agar	Merck Germany	1.05438.0500	VM811438747

Table 6. Incubation Conditions for each fungal species

ATCC 10231	aerobic	24-26 °C
ATCC 750	aerobic	24-26 °C
ATCC 6258	aerobic	25-30 °C
ATCC 90030	aerobic	20-25 °C
ATCC 16404	aerobic	20-25 °C
ATCC 9197	aerobic	24 °C
ATCC 9178	aerobic	24-26 °C
	TCC 10231 TCC 750 TCC 6258 TCC 90030 TCC 16404 TCC 9197 TCC 9178	TCC 10231aerobicTCC 750aerobicTCC 6258aerobicTCC 90030aerobicTCC 16404aerobicTCC 9197aerobicTCC 9178aerobic

\* EP 2.6.1 listed fungi strains

EZ-CFU standards are cultivated in fungal media and lyophilized in a stabilizing matrix.

Yeast material from Minerva Biolabs are cultivated in liquid fungal media, aliquoted and freeze down with 10-30% Glycerol.

Sporulating fungi are cultivated on fungal media agar plates and spores are collected in PBS/Tween, aliquoted and frozen with 10-30% glycerol.

### 5.5 Compendial culture method

The two fungi species listed in EP 2.6.1 (*Candida albicans* and *Aspergillus brasilliensis*) were spiked in DMEM + 5 % FBS and cultivated in thioglycolate medium and soya-bean casein medium (TSB) for 14 days according to the recommendation of the European Pharmacopoeia for compendial culture method described in EP 2.6.1.

### 5.6 Equipment

The following lab equipment was used for the study:

MB minerva biolabs sartorius stedim	Product Validation Report Microsart <sup>®</sup> ATMP Fungi/Microsart® ATMP Sterile Release	Dated: 04.12.2019 Document Version: 1 Document ID: VA07.01EN Page 11 of 40
---	---	---

#### Table 7. Lab Equipment at MB

Equipment	Equipment-ID	Manufacturer	Brand
qPCR cycler	R 04 0843, ES72	Corbett Research	Rotor-Gene 6000
qPCR cycler	275001289, ES12	Applied BioSystems	ABI Prism 7500
qPCR cycler	Model 401513; Serial No DE00700786	Agilent Technologies	Mx3005P
qPCR cycler	CFX96 Optics Ser. No. 785BR11826; C1000 Cycler Ser. No. CT015330	Bio-Rad	CFX Touch
qPCR cycler	272522531	Thermo Fisher	QuantStudio 5
Pipettes for master mix setup 10–300 μl 10–300 μl	E60, 15011121 E66, 15017290	Sartorius Sartorius	Biohit Picus Biohit Picus
Pipettes for Sample Handling 0.2-10 μl 10–300 μl 50-1000 μl	E69, 15023351 E70, 16010674 E71, 16009571	Sartorius Sartorius Sartorius Sartorius	Biohit Picus Biohit Picus Biohit Picus Biohit Picus
Pipettes for DNA Extraction 10-100µl 100-1000µl	E102, 18020324 E103, 18026710	Sartorius Sartorius	Tacta Tacta
Vortex	E29, VB4B016638	VWR	N/A
Glove box	E68, 22160256	GS Glovebox Systemtechnik GmbH	Glovebox P10RT2

### Table 8. Lab Equipment at SSB

Equipment	Equipment-ID	Manufacturer	Brand
qPCR cycler	Serial No: CT021642	Bio-Rad	CFX96 touch
Glovebox	12810/12811/12816	GS Glovebox Systemtechnik GmbH	Glovebox P10RT2
Laminar Flow	Heraeus LaminAir HLB 2448	Heraeus	LaminAir
Vortex	No 541-10000-00-0; Ser. No 020314813	Heidolph	REAX top
Micro centrifuge	Model AL220VAC; SN 053164	Roth	Rotilabo-Zentrifuge
Centrifuge	Order No. 75003280; Ser. No. 237292	Heraeus Instruments	Biofuge pico
Pipettes DNA-free 0.5 – 10 µl 2 – 20 µl 20 – 200 µl 100 – 1000 µl	16007668 16007703 16009618 16008275	Sartorius	Tacta
Electronic Pipettes DNA-free 10 – 300 µl	16005936	Sartorius	Picus NxT
Pipettes 0.5 – 10 μl 2 – 20 μl 10 – 100 μl 20 – 200 μl 100 – 1000 μl	16007685 16007711 16006996 16009619 16008272	Sartorius	Tacta

MB minerva biolabs* sartorius stedim	Product Validation Report Microsart <sup>®</sup> ATMP Fungi/Microsart® ATMP Sterile Release	Dated: 04.12.2019 Document Version: 1 Document ID: VA07.01EN Page 12 of 40
--	---	---

The following consumables were used:

Table 9. DNA-free lab ware used at MB

Article no.	Article name	Manufacturer / Supplier
72.706.400	Micro tubes, 1.5 ml, DNA-free	
72.991.103	PCR-tubes, Multiply-µStripPro	
70.1116.210	Biosphere filter tips 0.5 – 20 µl	Saratadt
70.760.212	Biosphere filter tips 2 – 100 µl	Saisteut
70.765.210	Biosphere filter tips 20 – 300 µl	
70.762.211	Biosphere filter tips 100 – 1000 µl	
710970X	PCR tubes, optical, DNA-free, high	
	profile, SingleCap, 8er-SoftStrips 0.2 ml	
710975X	PCR tubes, optical, DNA-free, low	Biozum
	profile, SingleCap, 8er-SoftStrips 0.2 ml	Бюдун
711200	PCR 0.1 ml 4-tubes & 4-Cap Strips	

Table 10. DNA-free lab ware used at SSB

Article no.	Article name	Manufacturer / Supplier
72.991.103	PCR-tubes, Multiply-µStripPro	
70.1116.210	Biosphere filter tips 0.5 – 20 µl	
70.760.212	Biosphere filter tips 2 – 100 µl	Sarstedt
70.765.210	Biosphere filter tips 20 – 300 µl	
70.762.211	Biosphere filter tips 100 – 1000 µl	
710970X	PCR tubes, optical, DNA-free, high	
	profile, SingleCap, 8er-SoftStrips 0.2 ml	Biozym
710975X	PCR tubes, optical, DNA-free, low	Вюдун
	profile, SingleCap, 8er-SoftStrips 0.2 ml	

# 6 Test Procedure

Sample preparation prior testing is strictly required for highest confidence and sensitivity. The design and performance of pre-analytical procedures are part of this study in respect of the intended use but cannot reflect the diversity of the sample material in total. The templates for the PCR analysis are prepared by direct extraction of the sample and subsequent PCR analysis.

### 6.1 Sample preparation

Microsart<sup>®</sup> ATMP Extraction and Microsart<sup>®</sup> ATMP Sterile Release kits are optimized to extract fungal genomic DNA from different sample matrices including cell culture samples, reducing handling steps and thus contamination to a minimum. The Internal Control DNA of Microsart<sup>®</sup> ATMP Fungi or Microsart<sup>®</sup> ATMP Sterile Release can be used to monitor the extraction process. Extraction of fungal DNA will be carried out according to the instruction manual.

In detail:

- 1. Transfer 1 ml sample into a provided DNA-free 1.5 ml processing tube (transparent cap)
- 2. Centrifuge at 16000 x g for 15 minutes
- 3. Remove the supernatant carefully and completely

Attention: Samples can only be inactivated or frozen after this sample collection step.

- 4. Add 500  $\mu I$  of Lysis Buffer to the sample
- **Optional:** Add 20 µl Internal Control DNA from Microsart<sup>®</sup> ATMP Fungi Kit or Microsart<sup>®</sup> ATMP Sterile Release to the sample to monitor the extraction process.
- **Remark:** In this validation study, the Internal Control was always used as a control of the PCR process, except during assay 1 of Table 17 where it was used as a control of the extraction process.
- 7. Vortex vigorously for 30 seconds until pellet is completely lysed
- 8. Heat at 80 °C for 10 minutes
- 9. Spin down at 16200 x g for 10 minutes
- 10. Remove supernatant carefully and completely, do not withdraw the pellet
- 11. Add 100  $\mu I$  Suspension Buffer (violet cap) and suspend pellet by vortexing

### 6.2 Analytical procedures

The detection of fungal DNA will be carried out according to the instruction manual.

In detail:

Rehydration of the Reagents:

- 1. Centrifuge tubes with lyophilized components (5 sec at maximum speed)
- Add 390 μl of Rehydration Buffer to the Fungi Mix (Microsart<sup>®</sup> ATMP Fungi) or 90 μl of Rehydration Buffer to each Fungi SR Mix (Microsart<sup>®</sup> ATMP Sterile Release).
- 3. Add appropriate amount of deionized, DNA-free water

Positive Control DNA 300 µl Internal Control DNA 800 µl

- 4. Incubate for 5 minutes at room temperature
- 5. Vortex and centrifuge again

### PCR master mix setup:

Total volume per reaction is 25  $\mu$ I including 10  $\mu$ I of sample. When setting up reactions, calculations include positive (PC) and negative controls (NTC). Pipet master mix into a 1.5 ml reaction tube and mix gently.

Pipetting scheme Microsart® A	<u> IMP Fungi:</u>	
	for 1 reaction	for 26 reactions
Fungi Mix	15 µl	390.0 µl
Internal Control DNA	1.0 µl	26.0 µl
Pipetting scheme Microsart® A	TMP Sterile Release:	
	for 1 reaction	for 6 reactions
Fungi SR Mix	15 µl	90.0 µl
Internal Control DNA	1.0 µl	6.0 µl

Attention: If the Internal Control DNA was added to the sample during DNA extraction, add 15 µL of the Fungi Mix or the Fungi SR Mix directly to each PCR tube.

### Loading the test tubes:

Aliquot 15  $\mu$ I of master mix into each PCR reaction tube. After pipetting the negative control (10  $\mu$ I of water or elution buffer of DNA extraction kit), the tube must be sealed before proceeding with the samples. Add 10  $\mu$ I of sample to each PCR reaction tube. Seal the tubes completely before proceeding with the positive control (10  $\mu$ I) in order to avoid cross contamination.

### Programming the qPCR cycler:

Program Step 1: Pre-incubationSettingHoldHold Temperature95°CHold Time3 min 0 sec

Program Step 2: Amplification

Setting	Cycling
Cycles	40
Denaturation	95 °C for 30 sec
Annealing	55 °C for 30 sec
Detection/ Elongation	60 °C for 45 sec

### **Result Interpretation:**

The presence of bacteria in the sample is indicated by an increasing fluorescence signal in the

I	MB minerva	Product Validation Report	Dated: 04.12.2019 Document Version: 1
	sartorius stedim	Release	Document ID: VA07.01EN Page 15 of 40

bacterial FAM<sup>\*\*</sup> channel during PCR. In order to interpret results accurately, a baseline has to be set. This threshold was defined as 10% of the maximum fluorescence level of the positive control.

The presence of fungi in the sample is indicated by an increasing fluorescence signal in the fungal FAM<sup>™</sup> channel during PCR.

Table 11. Result interpretation Microsart® ATMP Fungi and Microsart® ATMP Sterile Release

Detection of Fungi FAM™ channel	Internal control ROX™ channel	Interpretation
positive ( $C_q < 40$ )	irrelevant	Fungi positive
negative (no Cq)	negative (no C <sub>q</sub> )	PCR inhibition
negative (no C <sub>q</sub> )	positive*	Fungi negative

\*see chapter 6.3 for definition of positive

A successfully performed PCR without inhibition is indicated by an increasing fluorescence signal in the internal control channel. The provided Internal Control was added to the PCR master mix or as extraction control. Fungal DNA and Internal Control DNA are competitors in PCR. Because of the very low concentration of Internal Control in the PCR mix, the signal strength in this channel is reduced with increasing fungal DNA loads in the sample.

### 6.3 System suitability test criteria

Internal control (ROX<sup>TM</sup>) must show C<sub>q</sub>-values in the range of +/- 2 cycles of the no-template control (master mix control) if used as PCR control. If the internal control is used as extraction control it must show C<sub>q</sub>-values in the range of +/- 3 cycles of the no-template control (master mix control). To exclude contaminations, the extraction control and the master mix control (FAM<sup>TM</sup>) must be negative (no C<sub>q</sub>-value or C<sub>q</sub>-value > 40). The PCR positive control must show C<sub>q</sub>-values of 24 +/- 2 cycles (FAM<sup>TM</sup>).

### 6.4 Directives for action

During  $LOD_{95}$  determination (see Tables 12 and 13) 7 out of 8 NECs have to be negative. If more than one NEC is positive PCR was repeated. If NEC is confirmed positive, extraction was repeated. In case of positive NTC, PCR was repeated.

During specificity testing (see table 15), 6 of 8 NTCs have to be negative. In case more than two NTC were positive, PCR was repeated.

For robustness testing according to Tables 17A, step 1 and 2, two out of two NECs have to be negative. If NECs were positive PCR was repeated. If NEC was confirmed positive, extraction was repeated. In case of positive NTC, PCR was repeated.

For robustness testing as described in Tables 17A, step 3 and 4, seven out of eight NECs have to be negative. If NECs were positive PCR was repeated. If more than one NEC is positive PCR was repeated. If NEC is confirmed positive, extraction was repeated. In case of positive NTC, PCR was repeated.

MB minerva	Product Validation Report Microsart <sup>®</sup> ATMP Fungi/Microsart® ATMP Sterile Release	Dated: 04.12.2019 Document Version: 1
 sartorius stedim		Document ID: VA07.01EN Page 16 of 40

Due to the environmental abundance of fungal DNA it cannot be guaranteed that all cell culture samples used as spiking matrix are free of fungal DNA. Thus, in case of a positive signal for NEC that was confirmed after re-testing, samples were send for sequencing and parallel sterility testing at an external contract lab in order to distinguish between true- and false-positive signal. This way the NEC of the different sample matrices also provides information regarding specificity. In addition, sequence alignments were done to get an impression of the broad fungi detection capability of Microsart<sup>®</sup> ATMP Fungi and Microsart<sup>®</sup> ATMP Sterile Release.

During  $LOD_{95}$  determination and robustness for the Fungi SR mix of Microsart<sup>®</sup> ATMP Sterile Release (see Table 14), 1 out of 2 NEC/NTC have to be negative. If more than one NEC/NTC is positive, PCR was repeated. If NEC/NTC is confirmed positive, extraction was repeated.

### 6.5 Calculations

N/A

### 6.6 Reporting requirements

The reports generated by the qPCR machine were printed in color. All run information were printed, including protocol, sample identification, internal amplification control curves (ROX<sup>™</sup> filter) and target curves (FAM<sup>™</sup> filter) and filed according to the chapter structure of this validation plan. Sample identification should contain information on the species, the contained concentration in CFU/ml or GC/ml or alternatively the type of control (PC for Positive Control, NC for Negative Control, NTC for No Template Control and NEC for Negative Extraction Control).

### 6.7 Overview of experimental settings

### 6.7.1 LOD<sub>95</sub> determination / Fungi Detection Range

The experimental setup of each test is listed in the following tables. All tests of Table 12 were performed six times to have at least 24 results for each CFU concentration of each of the two fungal species listed in EP 2.6.1 and EP 2.6.27 available as EZ-CFU, and 48 results for NEC.

In the event that, after the first assay, two or more samples of a given concentration are negative, the following concentrations of the series were excluded from the study for the next assays.

Please be aware that due to variabilities in GE/CFU ratio of cultures, it is possible not to reproduce exactly the results presented in this validation study if other lot of EZ-CFU are used.

MB minerva biolabs* sartorius stedim	Product Validation Report Microsart <sup>®</sup> ATMP Fungi/Microsart® ATMP Sterile Release	Dated: 04.12.2019 Document Version: 1 Document ID: VA07.01EN Page 17 of 40
--	---	---

<u>Table 12.</u> Test setup for LOD<sub>95</sub> determination of fungal species listed in EP 2.6.1 and EP 2.6.27 with Microsart<sup>®</sup> ATMP Fungi

Dete	Detektion Limit							
	Spike DMEM + 5 % FBS with Candida albicans (EZ-CFU)							
4	99 CFU/ml	50 CFU/ml	25 CFU/ml	10 CFU/ml	5 CFU/ml	2.5 CFU/ml	1.25 CFU/ml	0 CFU/ml
· ·	→ 4 aliquots	$\rightarrow$ 4 aliquots	$\rightarrow$ 4 aliquots	$\rightarrow$ 4 aliquots	→ 4 aliquots	$\rightarrow$ 4 aliquots	→ 4 aliquots	→ 8 aliquots
	Extract DNA and perform PCR with 10 µI DNA extract in a final volume of 25 µI + IC. Add 2x PCR NTC and 2x PCR PC.							
	Spike DMEM + 5	% FBS with Aspen	rgillus brasilliensis (	(EZ-CFU)				
2	99 CFU/ml	50 CFU/ml	25 CFU/ml	10 CFU/ml	5 CFU/ml	2.5 CFU/ml	1.25 CFU/ml	0 CFU/ml
2	→ 4 aliquots	$\rightarrow$ 4 aliquots	$\rightarrow$ 4 aliquots	$\rightarrow$ 4 aliquots	$\rightarrow$ 4 aliquots	→ 4 aliquots	→ 4 aliquots	→ 8 aliquots
	Extract DNA and perform PCR with 10 µl DNA extract in a final volume of 25 µl + IC. Add 2x PCR NTC and 2x PCR PC.							

All tests of Table 13 were performed two times to generate at least eight results for each CFU concentration of each of the fungal species and 16 results for the NEC.

Table 13	. Test setup	for LOD <sub>95</sub>	determination
----------	--------------	-----------------------	---------------

Dete	ction Limit							
	Spike DMEM + 5 % FB	S with Candida tropic	alis					
3	99 CFU/ml	50 CFU/ml	25 CFU/ml	10 CFU/ml	5 CFU/ml	2.5 CFU/ml	0 CFU/ml	
5	$\rightarrow$ 4 aliquots	→ 4 aliquots	→ 4 aliquots	→ 4 aliquots	$\rightarrow$ 4 aliquots	→ 4 aliquots	→ 8 aliquots	
	Extract DNA and perfor	m PCR with 10 µl DN	A extract in a final vo	olume of 25 µl + IC. /	Add 2x PCR NTC ar	nd 2x PCR PC.		
	Spike DMEM + 5 % FB	S with Candida glabr	ata					
4	99 CFU/ml	50 CFU/ml	25 CFU/ml	10 CFU/ml	5 CFU/ml	2.5 CFU/ml	0 CFU/ml	
4	→ 4 aliquots	→ 4 aliquots	→ 4 aliquots	→ 4 aliquots	$\rightarrow$ 4 aliquots	$\rightarrow$ 4 aliquots	→ 8 aliquots	
	Extract DNA and perfor	m PCR with 10 µl DN	A extract in a final vo	olume of 25 µl + IC. /	Add 2x PCR NTC ar	nd 2x PCR PC.		
	Spike DMEM + 5 % FB	Spike DMEM + 5 % FBS with Candida krusei						
5	99 CFU/ml	50 CFU/ml	25 CFU/ml	10 CFU/ml	5 CFU/ml	2.5 CFU/ml	0 CFU/ml	
5	$\rightarrow$ 4 aliquots	→ 4 aliquots	$\rightarrow$ 4 aliquots	→ 4 aliquots	$\rightarrow$ 4 aliquots	→ 4 aliquots	→ 8 aliquots	
	Extract DNA and perform PCR with 10 µl DNA extract in a final volume of 25 µl + IC. Add 2x PCR NTC and 2x PCR PC.							
	Spike DMEM + 5 % FB	S with Aspergillus fur	nigatus					
6	99 CFU/ml	50 CFU/ml	25 CFU/ml	10 CFU/ml	5 CFU/ml	2.5 CFU/ml	0 CFU/ml	
0	$\rightarrow$ 4 aliquots	→ 4 aliquots	$\rightarrow$ 4 aliquots	$\rightarrow$ 4 aliquots	$\rightarrow$ 4 aliquots	→ 4 aliquots	→ 8 aliquots	
	Extract DNA and perform PCR with 10 µl DNA extract in a final volume of 25 µl + IC. Add 2x PCR NTC and 2x PCR PC.							
	Spike DMEM + 5 % FB	S with Penicillium cry	sogenum					
7	99 CFU/ml	50 CFU/ml	25 CFU/ml	10 CFU/ml	5 CFU/ml	2.5 CFU/ml	0 CFU/ml	
'	$\rightarrow$ 4 aliquots	→ 4 aliquots	→ 4 aliquots	→ 4 aliquots	$\rightarrow$ 4 aliquots	→ 4 aliquots	→ 8 aliquots	
	Extract DNA and perform PCR with 10 µl DNA extract in a final volume of 25 µl + IC. Add 2x PCR NTC and 2x PCR PC.							

The cut-off is defined as the lowest fungi concentration [CFU/ml] which leads in 95 % of the tests to a positive result (23/24 and 8/8 samples have to be positive). For  $LOD_{95}$  determination the instrument CFX96 touch was used.

Table 14: Test setup for LOD<sub>95</sub> determination with Fungi SR mix of Microsart<sup>®</sup> ATMP Sterile Release.

Detection L	Detection Limit					
	Spike DMEM + 5 % FBS with Aspergillus brasiliensis					
8	2 aliquots 99 CFU/mI + 1 NEC	2 aliquots 50 CFU/ml + 1 NEC				
0	Extract DNA and perform PCR with 10 $\mu$ I DNA extract in a final volume of 25 $\mu$ I + IC. Add 1x PCR NTC and 1x PCR PC.	Extract DNA and perform PCR with 10 µl DNA extract in a final volume of 25 µl + IC. Add 1x PCR NTC and 1x PCR PC.				
	Spike DMEM + 5 % FBS with Candida albicans	· · ·				
0	2 aliquots 99 CFU/mI + 1 NEC	2 aliquots 50 CFU/mI + 1 NEC				
9	Extract DNA and perform PCR with 10 µl DNA extract in a final volume of 25 µl + IC. Add 1x PCR NTC and 1x PCR PC.	Extract DNA and perform PCR with 10 µl DNA extract in a final volume of 25 µl + IC. Add 1x PCR NTC and 1x PCR PC				
	Spike DMEM + 5 % FBS with Candida krusei					
10	2 aliquots 99 CFU/ml + 1 NEC	2 aliquots 50 CFU/ml + 1 NEC .				
10	Extract DNA and perform PCR with 10 µl DNA extract in a final	Extract DNA and perform PCR with 10 µl DNA extract in a final				
		volume of 25 µr + 10. Add 1x FCR NTC and 1x PCR PC				

All tests of Table 14 were performed four times to generate eight data points for each CFU concentration of each of the fungal species.

MB minerva biolabs* sartorius stedi	Product Validation Report Microsart <sup>®</sup> ATMP Fungi/Microsart <sup>®</sup> ATMP Sterile Release	Dated: 04.12.2019 Document Version: 1 Document ID: VA07.01EN Page 18 of 40
---	---	---

### 6.7.2 PCR specificity

The specificity of the method was tested by spiking the PCR master mix with specific and nonspecific DNA as described in Table 15. This assay was performed twice in order to collect at least 16 results for each species.

Table 15. Test setup for specificity testing with genomic DNA

Sp	pecificity	
	Spike PCR master mix with 10 GC/PCR of specific DN	A
	Candida albicans $\rightarrow$ 8 aliquots	0 CC/PCR
1	Candida guilliermondii $\rightarrow$ 8 aliquots	
	Candida haemulonii $\rightarrow$ 8 aliquots	$\rightarrow$ 0 allyuots
	Perform PCR with 10 µI DNA solution in a final volume	of 25 µl + IC. Add 2x PCR PC.
	Spike PCR master mix with 10 <sup>5</sup> GC/PCR of non-specif	ic DNA
	Bacillus subtilis $\rightarrow$ 8 aliquots	
2	Pseudomonas aeruginosa $\rightarrow$ 8 aliquots	
	Legionella pneumophila $\rightarrow$ 8 aliquots	$\rightarrow$ o aliquois
	Perform PCR with 10 µl DNA solution in a final volume	of 25 µl + IC. Add 2x PCR PC.

### 6.7.3 Comparison of Microsart<sup>®</sup> ATMP Fungi with compendial sterility test

The following assays described in Table 16, compares the Microsart<sup>®</sup> ATMP Fungi system with the compendial sterility test.

Table 16: Test setup for comparison between Microsart<sup>®</sup> ATMP Fungi and compendial sterility test (Accuracy and precision)

Spe	pecificity: Comparison with culture method with defined starting material quantity at external contract lab						
	Spike DMEM + 5 % FBS with Candida albicans at 2x LOD <sub>95</sub> , LC	$D_{95}$ and $LOD_{95}/2$ . One aliquot without spike is processed as NC.					
1	1 ml of each sample is used for the sterility test (direct inoculation) at the external contract lab L+S AG	Extract DNA from 1ml starting material with Microsart <sup>®</sup> ATMP Extraction. Perform the qPCR according to Microsart <sup>®</sup> ATMP Fungi.					
	Spike DMEM + 5 % FBS with Aspergillus brasilliensis at 2x LOE as NC.	$D_{95},$ LOD_{95} and LOD_{95}/2. One aliquot without spike is processed					
2	1 ml of each sample is used for the sterility test (direct inoculation) at the external contract lab L+S AG	Extract DNA from 1ml starting material with Microsart <sup>®</sup> ATMP Extraction. Perform the qPCR according to Microsart <sup>®</sup> ATMP Fungi.					

The suspensions of the two listed species were diluted to generate the appropriate concentrations and split into aliquots. A sample of each concentration were used for sterility test (direct inoculation) at L+S. In parallel, aliquots were extracted in duplicates and analyzed on a CFX96 cycler.

### 6.7.4 Robustness

Robustness testing allowed to test the reproducibility of the assay when the conditions of the experiments were slightly modified. Thus, as detailed in Table 17, we tested the Microsart<sup>®</sup> ATMP Fungi system with cell suspension, with different PCR cyclers, with free DNA as well as different laboratory environment and operators. Assay 1 to 4 were performed twice.

### Table 17. Test setup for robustness testing with Microsart® ATMP Fungi

Ro	oustness								
	Dilute cell samples listed	in table 4 in DMEM with	n 5 % FBS to generate a	concentration of 106 and 105 c	ells/ml.				
	Spike with 99 CFU/ml of the fungi with the highest $LOD_{95}$ value selected from the species listed in Table 12 and no spike (NEC) $\rightarrow$ 2 aliquots								
1	$\rightarrow$ 2 aliquots with 10° cell	s/mi							
	$\rightarrow$ 2 aliquots with 10° cell	s/mi							
	Add 20 µl Internal Contro	I DINA INTO IVSIS DUTTER TO	o monitor the extraction p	process. Extract DNA. Perform	PCR with 10 µI DNA				
	extract in a final volume of 25 µl. Add 2x PCR NTC and 2x PCR PC (add IC to NTC and PC reactions).								
	Spike DMEM + 5 % FBS with 99 CF 0/ml of the fungi with the highest LOD <sub>95</sub> NEC (DMEM + 5% FBS)								
2	$\rightarrow$ 8 allquots		treation of final values of						
	Extract DNA and perform	A DI 7500	Ktract in a final volume of		and 2X PCR PC.				
	Rolor Gene 6000	ABI 7300	MX3005P	CF 790	Quant Studio 5				
	Spike water with Candida	a albicans gDINA.	4.02 0.0/201	10.00/21					
	10 <sup>+</sup> GC/ml	10° GC/mi		10 GC/mi					
	$\rightarrow$ 8 aliquots	$\rightarrow$ 8 aliquots	$\rightarrow$ 8 allquots	$\rightarrow$ 8 aliquots	$\rightarrow$ 8 aliquots				
3	Extract DNA		(						
	Perform PCR with 10 µl c	of extract in a final volun	ne of 25 $\mu$ I + IC.						
	In parallel, perform a star	in parallel, perform a standard PCR serie with 2x10µl of each of the spiked water (not extracted).							
	Add 2x PCR NTC and 2x								
	Spike water with cell cultu	ure suspension (Vero ce	ells; 10 <sup>+</sup> cells/ml) and Cal	ndida albicans gDNA.					
	10 <sup>4</sup> GC/ml	10 <sup>3</sup> GC/ml	10 <sup>2</sup> GC/ml	10 GC/ml	0 GC/ml (NEC)				
	$\rightarrow$ 8 aliquots	$\rightarrow$ 8 aliquots	$\rightarrow$ 8 aliquots	$\rightarrow$ 8 aliquots	$\rightarrow$ 8 aliquots				
4	Extract DNA								
	Perform PCR with 10 µl of extract in a final volume of 25 µl + IC.								
	In parallel, perform a standard PCR serie with 2x10ul of each of the spiked water (not extracted).								
	Add 2x PCR PC.								
	Extract DNA from culture	media listed in Table 2	and from DMEM + 5 % F	BS and perform PCR with 10	µI DNA extract in a final				
5	volume of 25 µl + IC. Add	2x PCR PC.			-				
	12 x 8 for DMEM: 1 x 8 for other culture media								

# 7 Study Results

The study conditions had to provide information on all relevant validation parameters requested by European Pharmacopoeia (Ph. Eur.) chapter 5.1.6 part 4-1-1, Primary validation to be performed by the supplier.

### 7.1 LOD<sub>95</sub> Detection Limit

As the method employed is used only to obtain a qualitative result, proof of linearity is not required. If however the concept of linearity is extended to cover the working range, the detection limit becomes extremely important. In practice, the detection limit is determined in the form of the positive threshold (i.e. the cut-off point in the form of the minimum number of amplified target sequences by volume positively detected in 95 % of the sample series).

Link	Procedure	Acceptance Criterion	Results / LOD <sub>95</sub>
See Table 12; 1 and 2 See Table 13; 3 to 7 See Table 14; 8 and 9	CFU-quantified fungal suspensions (Table 3) were diluted, according to their individual cell count, in DMEM + 5 % FBS to prepare suspensions with concentrations from 99 to 0 CFU/ml. Individual dilution series were prepared for the two fungal species listed in EP 2.6.1 and EP 2.6.27, and for another five fungal species. Dilutions from 99 to 0 CFU/ml were tested according to test procedure described chapter 6.	The cut-off is defined as the lowest fungi concentration [CFU/mI] which leads in 95 % of the tests to a positive result (23/24 and 8/8 samples have to be positive). LOD <sub>95</sub> must be $\leq$ 99 CFU	Passed (LOD <sub>95</sub> comprised between 10 CFU and 99 CFU)

### Candida albicans

CFU/ml						Mean	
	Run 1	31.32	31.90	32.78	32.80	32.20	
	Run 2	32.96	32.88	33.07	32.25	32.79	
00	Run 3	32.29	32.81	36.03	32.09	33.30	24/24
99	Run 4	32.46	32.14	32.29	32.33	32.30	24/24
	Run 5	32.32	32.55	32.71	32.36	32.48	
	Run 6	32.58	31.48	31.89	32.43	32.09	
	Run 1	33.15	33.79	34.11	34.44	33.87	23/24
	Run 2	34.25	33.86	33.04	35.03	34.04	
50	Run 3	33.59	33.90	32.63	33.89	33.50	
50	Run 4	34.04	32.94	34.27	33.81	33.76	
	Run 5	No Cq	34.77	32.82	34.48	34.02	
	Run 6	32.58	32.57	32.82	34.81	33.19	
	Run 1	33.42	34.72	34.88	35.32	34.58	
	Run 2	34.67	37.19	33.28	36.08	35.30	
25	Run 3	34.96	37.20	38.18	No Cq	36.78	21/24
25	Run 4	37.96	34.90	35.11	34.59	35.64	21/24
	Run 5	33.55	No Cq	35.77	No Cq	34.66	
	Run 6	34.51	35.33	36.17	34.90	35.23	

· · · · · · · · · · · · · · · · · · ·	MB minerva biolabs*	Jim Microsa	Product Validation Report Microsart <sup>®</sup> ATMP Fungi/Microsart® ATMP Sterile Release			Dated: 04.12. Document Ve Document ID: Page 21 of 40	2019 ersion: 1 : VA07.01EN )		
		Due 4	25.05	20.40	07.07	07.00	00.74		

	Run 1	35.85	36.48	37.27	37.38	36.74	
	Run 2	No Cq	No Cq	37.00	34.65	35.82	
10	Run 3	No Cq	14/24				
10	Run 4	No Cq	35.93	No Cq	37.11	36.52	14/24
	Run 5	35.04	No Cq	No Cq	38.91	36.97	
	Run 6	35.54	36.26	35.84	37.52	36.29	

# Candida Albicans (Microsart® ATMP Sterile Release)

CFU/ml				Mean	
99	Run 1	31.63	31.96	31.79	
	Run 2	34.21	32.41	33.31	Q/Q
	Run 3	30.10	30.12	30.11	0/0
	Run 4	30.31	31.12	30.71	
	Run 1	33.27	32.16	32.71	
50	Run 2	33.98	35.53	34.75	Q/Q
	Run 3	31.99	31.59	31.79	0/0
	Run 4	32.88	32.84	32.86	

### Aspergillus brasiliensis

CFU/ml						Mean	
	Run 1	32.32	35.00	33.22	33.01	33.39	
	Run 2	33.67	33.16	33.58	33.60	33.50	
00	Run 3	36.71	33.73	33.64	34.37	34.61	04/04
99	Run 4	35.30	36.14	35.24	33.35	35.01	24/24
	Run 5	35.05	33.66	33.10	33.92	33.93	
	Run 6	35.88	34.05	34.86	34.20	34.74	
	Run 1	35.80	34.68	33.07	33.88	34.36	
	Run 2	34.66	33.43	34.10	34.42	34.15	
50	Run 3	35.06	35.01	33.61	34.60	34.57	21/21
50	Run 4	33.85	38.19	35.56	34.70	35.57	24/24
	Run 5	35.26	35.39	35.04	35.39	35.27	
	Run 6	35.81	38.35	36.26	34.44	36.21	
	Run 1	No Cq	39.47	37.41	35.42	37.43	
	Run 2	35.02	No Cq	36.41	35.60	35.67	
25	Run 3	No Cq	38.48	36.55	39.44	38.16	18/2/
25	Run 4	35.45	35.42	No Cq	No Cq	35.44	10/24
	Run 5	34.99	37.80	37.37	39.29	37.36	
	Run 6	38.51	35.66	34.97	No Cq	36.38	
	Run 1	34.74	36.48	No Cq	35.35	35.52	
	Run 2	37.25	37.67	37.83	No Cq	37.58	
10	Run 3	34.69	34.79	No Cq	No Cq	34.74	11/2/
10	Run 4	37.94	37.83	No Cq	No Cq	37.88	11/24
	Run 5	No Cq					
	Run 6	34.79	No Cq	No Cq	No Cq	34.79	

# Aspergillus brasiliensis (Microsart® ATMP Sterile Release)

CFU/ml				Mean		
99	Run 1	33.96	33.72	33.84		
	Run 2	32.77	33.83	33.30	8/8	
	Run 3	33.34	33.23	33.29		
	Run 4	33.66	34.89	34.28		
	Run 1	34.67	35.10	34.89		
50	Run 2	33.96	33.97	33.97	0/0	
	Run 3	33.39	33.69	34.54	0/0	
	Run 4	36.14	34.16	35.15		

### Candida krusei

CFU/ml						Mean	
00	Run 1	33.69	32.83	33.45	33.39	33.34	0/0
99	Run 2	33.25	32.10	31.98	32.37	32.42	0/0
50	Run 1	33.86	35.09	33.84	34.11	34.23	0/0
50	Run 2	34.23	34.96	34.20	34.55	34.48	0/0
25	Run 1	34.00	36.83	35.00	34.39	35.06	C/0
25	Run 2	No Cq	No Cq	36.73	37.17	36.95	0/0
10	Run 1	No Cq	35.33	36.64	37.25	36.41	A /O
10	Run 2	No Cq	37.34	No Cq	No Cq	37.34	4/0

### Candida krusei (Microsart<sup>®</sup> ATMP Sterile Release)

CFU/ml				Mean		
00	Run 1	33.97	34.90	34.44		
	Run 2	32.84	31.81	32.33	0/0	
99	Run 3	33.70	31.10	32.40	0/0	
	Run 4	32.88	33.66	33.27		
	Run 1	35.03	35.28	35.16		
50	Run 2	34.14	33.46	33.80	0/0	
	Run 3	34.52	32.54	33.53	0/0	
	Run 4	35.15	34.84	35.00		

### Candida tropicalis

CFU/ml						Mean	
00	Run 1	31.85	32.10	31.65	31.75	31.84	0/0
99	Run 2	30.35	31.85	31.15	31.04	31.10	0/0
50	Run 1	33.10	32.71	34.66	34.00	33.62	0/0
50	Run 2	33.06	30.79	32.32	32.03	32.05	0/0
25	Run 1	32.87	38.61	34.39	37.15	35.76	0/0
25	Run 2	35.42	31.83	35.96	34.93	34.53	0/0
10	Run 1	38.85	34.83	36.28	35.48	36.36	0/0
10	Run 2	34.63	33.96	33.66	36.28	34.63	0/0
5	Run 1	37.32	38.69	39.83	No Cq	38.61	E /0
5	Run 2	36.43	No Cq	No Cq	37.29	36.86	5/6

### Candida glabrata

CFU/ml						Mean	
00	Run 1	33.54	33.34	37.72	35.42	35.01	0/0
99	Run 2	33.12	33.71	33.21	34.21	33.56	0/0
50	Run 1	34.32	35.22	37.22	33.22	35.00	Q/Q
50	Run 2	34.43	35.26	34.35	34.62	34.66	0/0
25	Run 1	37.43	35.74	38.34	39.70	37.80	Q/Q
25	Run 2	36.45	36.03	38.26	34.65	36.35	0/0
10	Run 1	39.12	No Cq	No Cq	No cq	39.12	1/9
10	Run 2	38.48	No Cq	36.43	38.12	37.68	4/0

### Aspergillus fumigatus

CFU/ml						Mean	
00	Run 1	34.10	36.68	33.19	36.14	35.03	0/0
99	Run 2	34.75	34.50	33.77	32.24	33.81	0/0
50	Run 1	No Cq	35.30	No Cq	37.50	36.40	C/0
50	Run 2	34.48	36.19	38.75	34.79	36.05	0/0
25	Run 1	38.19	No Cq	No Cq	No Cq	38.19	4/0
25	Run 2	36.73	38.07	No Cq	38.45	37.75	4/0

### Penicillium chrysogenum

CFU/ml						Mean	
00	Run 1	34.16	34.36	33.05	31.89	33.37	0/0
99	Run 2	32.33	34.01	37.24	34.32	34.47	0/0
50	Run 1	33.56	33.55	34.55	38.78	35.11	7/0
50	Run 2	34.70	36.23	32.18	No Cq	34.37	1/0
25	Run 1	No Cq	38.59	37.33	37.59	37.84	C/0
25	Run 2	36.85	37.57	No Cq	39.27	37.90	0/0
10	Run 1	33.61	No Cq	37.76	No Cq	35.69	2/0
10	Run 2	No Cq	2/0				

### LOD<sub>95</sub> summary

Species	LOD <sub>95</sub>
Table 13	
Candida albicans	50 CFU/ml
Aspergillus brasilliensis	50 CFU/ml
Table 14	
Candida tropicalis	10 CFU/ml
Candida glabrata	25 CFU/ml
Candida krusei	50 CFU/ml
Aspergillus fumigatus	99 CFU/ml
Penicillium chrysogenum	99 CFU/ml

### 7.2 Specificity

Specificity testing was comprehensively covered during sensitivity and robustness testing. During evaluation of sensitivity, 7 different fungal species were tested in order to determine the limit of detection when spiked into a complex sample matrix (DMEM + 5 % FBS). To extend our analysis, an *in silico* study was performed in order to predict the detectability of the most common fungi contaminations that could occur during the processing of ATMP products, based on the most recent references about this topic.

### 7.2.1 Sequence Alignment

Procedure	Acceptance Criterion	Results
Comparison of all primer sequences with a genomic database of fungal species that might contaminate pharmaceutical products. This provides additional <i>in silico</i> information about the putative power of detection of the kit.	Fungal species showing ≤ 2 nucleotides mismatch each primer in the alignment with the 18S rRNA genome are considered specifically detectable.	A vast majority of the listed species are detectable based on sequence alignement.

Dated: 04.12.2019 Document Version: 1 Document ID: VA07.01EN Page 24 of 40

Genus	Reference	Coverage
Alternaria	2,3	97.7 %
Aspergillus	1	95.3 %=
Aureobasidium	6	93.5 %
Bipolaris	2	98 %
Candida	1	86.3 %
Chaetomium	6	3.6%
Cladosporium	2,3	95.5 %
Curvularia	2	100 %
Epidermophyton	4	100 %
Exserohilum	2	97.4 %
Fusarium	2, 3, 6	95.9 %
Memnoniella (Stachybotrys)	6	86,7 %
Microsporum	4	100 %
Myrothecium	6	100 %
Paecilomyces	6	100%
Penicillium	2, 3, 5, 6	98.2 %
Malassezia*	2	0.1 %
Rhizopus	6	4 %
Scopulariopsis	6	0 %
Trichoderma	6	98 %
Trichophyton	4	100 %

\*This genus is normally part of the skin microbiota, but might be involved in skin disorders in patients under parenteral nutrition, immunocompromised patients with increased length of stay in intensive care, very low-birth-weight and premature infants (Source: 7;8)

#### References:

1. LightCycler® SeptiFast Test MGRADE | Roche Molecular Diagnostics [Internet]. [zitiert 29. März 2017]. Verfügbar unter: https://molecular.roche.com/assays/lightcycler-septifast-test-mgrade/

2. Vijayakumar R, Saleh Al-Aboody M, Sandle T. A review of melanized (black) fungal contamination in pharmaceutical products-incidence, drug recall and control measures. J Appl Microbiol. April 2016;120(4):831–41.

3. A review of fungal contamination in pharmaceutical products and phenotypic identification of contaminants by conventional methods [Internet]. ResearchGate. [zitiert 29. März 2017]. Verfügbar unter:

https://www.researchgate.net/publication/275335972\_A\_review\_of\_fungal\_contamination\_in\_pharmaceutical\_products\_and\_phenoty pic\_identification\_of\_contaminants\_by\_conventional\_methods

4. Havlickova B, Czaika VA, Friedrich M. Epidemiological trends in skin mycoses worldwide. Mycoses. September 2008;51 Suppl 4:2– 15.

 Sandle T. A review of cleanroom microflora: types, trends, and patterns. PDA J Pharm Sci Technol. August 2011;65(4):392–403.
 Strains for Quality Control, e.g. of Media, Rapid Identification Systems, Disinfectant, Sterilization, Antibiotic or Fungus Resistance Testing, and Miscellaneous Tests [Internet]. https://www.dsmz.de/catalogues/catalogue-microorganisms/groups-of-organisms-and-their-applications/quality-control-strains.html

7. Velegraki A, Cafarchía C, Gaintanis G, latta R, Boekhout T. Malassezia Infections in Humans and Animals: Pathophysiology, Detection, and Treatment. PLoS Pathog. 2015 Jan 8;11(1):e1004523.

8. latta R, Cafarchia C, Cuna T, Montagna O, Laforgia N, Gentile O, Rizzo A, Boekhout T, Otranto D, Montagna MT. Bloodstream infections by Malassezia and Candida species in critical care patients. Med Mycol. 2014 Apr;52(3):264-9.

#### 7.2.2 Fungi Detection Range

Link	Procedure	Acceptance Criterion	Results
See Table 12; 1 and 2 See Table 13; 3 to 7 See Table 14; 8 to 9	All fungi listed in Table 12, 13 and 14 were tested at concentrations between 0-99 CFU/ml (spiked into DMEM + 5 % FBS) in 3; 4 or 8 replicates	99 CFU/mI must be tested positive for all species.	Passed

	Average C <sub>q</sub> value at 99 CFU/ml	% detected at 99 CFU/ml
Tested with ATMP Fungi		
Candida albicans	32.53	100
Aspergillus brasilliensis	34.20	100
Candida krusei	32.88	100
Candida tropicalis	31.47	100
Candida glabrata	34.28	100
Aspergillus fumigatus	34.42	100
Penicillium chrysogenum	33.92	100
Tested with Microsart® ATMP Sterile Release	Average C <sub>q</sub> value at 99 CFU/ml	% detected at 99 CFU/mI
Candida albicans	31.48	100
Aspergillus brasiliensis	33.68	100
Candida krusei	33.11	100

7.2.3	Sample	Matrix	effects /	'Cross	reactivity
-					

Link	Procedure	Acceptance Criterion	Results
See Table 4 See Table 17, 1 (NEC)	All cell samples listed in Table 4 were tested in duplicates without fungal spike (NEC during robustness testing)	All samples shall show a negative result.	Passed

			Results
	No Cq	No Cq	
Hela	No Cq	No Cq	0/8
	No Cq	No Cq	0/0
	No Cq	No Cq	
	No Cq	No Cq	
Vara	No Cq	No Cq	0/9
vero	No Cq	No Cq	0/8
	No Cq	No Cq	
	No Cq	No Cq	
	No Cq	No Cq	0/8
CHO-KI	No Cq	No Cq	0/8
	No Cq	No Cq	
	No Cq	No Cq	
HDRMC	No Cq	No Cq	0/8
HE DIVIC	No Cq	No Cq	0/8
	No Cq	No Cq	
	No Cq	No Cq	
lurkat	No Cq	No Cq	0/8
Vuinat	No Cq	No Cq	0/0
	No Cq	No Cq	

### 7.2.4 Specificity of PCR with genomic DNA

Link	Procedure	Acceptance Criterion	Results
See Table 15; 1 and 2	All fungi listed in Table 15 were tested with 10 and 0 GC (spiked directly into PCR). All bacteria listed in Table 15 were tested with 10 <sup>5</sup> and 0 GC (spiked directly into PCR).	All fungi species must be detected at 10 GC/PCR. No Bacteria Species shall be detected.	Passed (one sample out of 16 was positive for B. subtilis. The very low occurrence indicates that this was due to a contamination and not to a cross reactivity and was consequently not sequenced)

MB minerva biolabs, sartorius stedim	Product Validation Report Microsart <sup>®</sup> ATMP Fungi/Microsart® ATMP Sterile Release	Dated: 04.12.2019 Document Version: 1 Document ID: VA07.01EN Page 26 of 40
	Dun 4 Dun 9	

	Run 1	Run 2	
	No C <sub>q</sub>	No C <sub>q</sub>	
	No C <sub>q</sub>	No C <sub>q</sub>	
	No C <sub>q</sub>	No C <sub>q</sub>	
	No C <sub>q</sub>	No C <sub>q</sub>	0/16
	No C <sub>q</sub>	No C <sub>q</sub>	0/10
	No C <sub>q</sub>	No C <sub>q</sub>	
	No C <sub>q</sub>	No C <sub>q</sub>	
	No C <sub>a</sub>	No C <sub>a</sub>	

(Sensitivity)	Run 1	Run 2	
	29.44	29.28	
	29.36	29.34	
	29.38	29.31	
10 GC/PCR Candida	29.24	29.29	16/16
albicans	29.39	29.31	10/10
	29.21	29.39	
	29.64	29.37	
	29.20	29.28	
	34.42	34.23	
	35.32	34.20	
	34.84	35.11	
10 GC/PCR Candida	34.37	34.60	16/16
guilliermondii	33.91	34.14	10/10
	34.30	34.60	
	34.69	34.91	
	34.55	34.62	
	29.88	29.95	
	29.60	29.63	
	29.83	29.79	
10 GC/PCR Candida	30.01	30.20	16/16
haemulonii	30.05	29.87	10/10
	29.96	30.07	
	29.79	30.00	
	29.56	29.63	
Bacteria species (Cross reactivity)	Run 1	Run 2	
Bacteria species (Cross reactivity)	Run 1 No C <sub>a</sub>	Run 2	
Bacteria species (Cross reactivity)	Run 1 No C <sub>q</sub> 38.11	<b>Run 2</b> No C <sub>q</sub> No C <sub>g</sub>	
Bacteria species (Cross reactivity)	<b>Run 1</b> No C <sub>q</sub> <b>38.11</b> No C <sub>g</sub>	<b>Run 2</b> No C <sub>q</sub> No C <sub>q</sub>	
Bacteria species (Cross reactivity) 10 <sup>5</sup> GC/PCR <i>Bacillus</i>	No Cq           38.11           No Cq           No Cq	Run 2 No C <sub>q</sub> No C <sub>q</sub> No C <sub>q</sub>	1/40
Bacteria species (Cross reactivity) 10 <sup>5</sup> GC/PCR <i>Bacillus</i> <i>subtilis</i>	Run 1           No Cq           38.11           No Cq           No Cq           No Cq           No Cq	Run 2           No Cq           No Cq           No Cq           No Cq           No Cq           No Cq	1/16
Bacteria species (Cross reactivity) 10 <sup>5</sup> GC/PCR <i>Bacillus</i> <i>subtilis</i>	No Cq           38.11           No Cq           No Cq           No Cq           No Cq           No Cq	Run 2 No C <sub>q</sub> No C <sub>q</sub> No C <sub>q</sub> No C <sub>q</sub> No C <sub>q</sub>	1/16
Bacteria species (Cross reactivity) 10 <sup>5</sup> GC/PCR <i>Bacillus</i> <i>subtilis</i>	Run 1           No Cq           38.11           No Cq	Run 2           No Cq	1/16
Bacteria species (Cross reactivity) 10 <sup>5</sup> GC/PCR <i>Bacillus</i> <i>subtilis</i>	Run 1           No Cq           38.11           No Cq	Run 2           No Cq	1/16
Bacteria species (Cross reactivity) 10 <sup>5</sup> GC/PCR <i>Bacillus</i> <i>subtilis</i>	Run 1           No Cq           38.11           No Cq	Run 2           No Cq	1/16
Bacteria species (Cross reactivity) 10 <sup>5</sup> GC/PCR <i>Bacillus</i> <i>subtilis</i>	Run 1           No Cq           38.11           No Cq	Run 2           No Cq	1/16
Bacteria species (Cross reactivity)	Run 1           No Cq           38.11           No Cq	Run 2           No Cq	1/16
Bacteria species (Cross reactivity) 10 <sup>5</sup> GC/PCR <i>Bacillus</i> <i>subtilis</i>	Run 1           No Cq           38.11           No Cq	Run 2           No Cq	1/16
Bacteria species (Cross reactivity) 10 <sup>5</sup> GC/PCR <i>Bacillus</i> <i>subtilis</i> 10 <sup>5</sup> GC/PCR <i>Pseudomonas</i>	Run 1           No Cq           38.11           No Cq	Run 2           No Cq	1/16
Bacteria species (Cross reactivity)	Run 1         No Cq         38.11         No Cq	Run 2           No Cq	1/16 0/16
Bacteria species (Cross reactivity) 10 <sup>5</sup> GC/PCR Bacillus subtilis 10 <sup>5</sup> GC/PCR Pseudomonas aeruginosa	Run 1           No Cq           38.11           No Cq	Run 2           No Cq	1/16
Bacteria species (Cross reactivity)	Run 1           No Cq           38.11           No Cq	Run 2           No Cq	1/16 0/16
Bacteria species (Cross reactivity)	Run 1           No Cq           38.11           No Cq	Run 2           No Cq	1/16 0/16
Bacteria species (Cross reactivity)	Run 1           No Cq           38.11           No Cq	$\begin{array}{c} \textbf{Run 2} \\ No C_q \\ No $	1/16 0/16
Bacteria species (Cross reactivity)	Run 1           No Cq           38.11           No Cq	$\begin{array}{c} \textbf{Run 2} \\ No C_q \\ No $	1/16 0/16
Bacteria species (Cross reactivity)	Run 1           No Cq           38.11           No Cq	$\begin{array}{c} \textbf{Run 2} \\ No C_q \\ No $	0/16
Bacteria species (Cross reactivity)	Run 1           No Cq           38.11           No Cq           No Cq	$\begin{array}{c} \textbf{Run 2} \\ No C_q \\ No $	0/16
Bacteria species (Cross reactivity) 10 <sup>5</sup> GC/PCR Bacillus subtilis 10 <sup>5</sup> GC/PCR Pseudomonas aeruginosa 10 <sup>5</sup> GC/PCR Legionella pneumophila	Run 1           No Cq           38.11           No Cq	$\begin{array}{c} \textbf{Run 2} \\ No C_q \\ No $	1/16 0/16
Bacteria species (Cross reactivity) 10 <sup>5</sup> GC/PCR Bacillus subtilis 10 <sup>5</sup> GC/PCR Pseudomonas aeruginosa 10 <sup>5</sup> GC/PCR Legionella	Run 1           No Cq           38.11           No Cq           No Cq	$\begin{array}{c} \textbf{Run 2} \\ No C_q \\ No $	1/16 0/16 0/16

### 7.2.5 Comparison of Microsart® ATMP Fungi with the compendial culture method

Link	Procedure	Acceptance Criterion	Results
See Table 16	For each species listed in Table 16, a dilution series was performed. 1 ml was extracted with Microsart® ATMP Extraction and analyzed with Microsart® ATMP Fungi. In parallel, 1 ml of the species listed in Table 16 were tested with the compendial culture method (direct inoculation) by an external lab.	Microsart <sup>®</sup> ATMP Fungi shall show equal or higher sensitivity than the culture method. All samples containing spikes at concentrations of 2x LOD <sub>95</sub> and LOD <sub>95</sub> shall show a positive result with Microsart <sup>®</sup> ATMP Fungi.	Passed

	Microsart <sup>®</sup> ATMP Fungi		Compendial culture method (External)			
	2x LOD <sub>95</sub>	LOD <sub>95</sub>	LOD <sub>95</sub> /2	2x LOD <sub>95</sub>	LOD <sub>95</sub>	LOD <sub>95</sub> /2
Candida albicans	32.25 31.94	32.27 32.12	33.96 32.96	2/2 Positive C. albicans	2/2 Positive C. albicans	0/2 Positive
Aspergillus brasiliensis	34.38 32.40	37.06 33.17	34.94 34.20	2/2 Positive A. brasisliensis	2/2 Positive A. brasisliensis	2/2 Positive A. brasisliensis

### 7.3 Robustness

Six samples containing different cell lines in a relevant cell density and in typical cell culture media and buffer were spiked with 99 CFU of one of the fungal species detected with the highest  $LOD_{95}$ value during LOD determination (selected from the two fungal species listed in EP 2.6.1 and EP 2.6.27, available as EZ-CFU). Additionally, those two species were tested at three concentrations around their  $LOD_{95}$  in comparison with the culture method described in EP 2.6.1.

### 7.3.1 Cell culture samples spiked with fungi

Link	Procedure	Acceptance Criterion	Results
See Table 17; 1	Five samples containing different cell lines in a relevant cell density and in typical cell culture media and buffer were spiked with 99 CFU/ml of the fungi which was detected with the highest LOD <sub>95</sub> value during LOD <sub>95</sub> determination (selected from the two fungi mentioned in the EP 2.6.1 and EP 2.6.27).	All spiked samples shall show a positive result.	Passed

	Aspergillus brasiliensis 99 CFU (FAM™)								
	10º ce	ells/ml	Positive		10⁵ ce	ells/ml	Positive		
Holo	37.54	31.26	A / A		33.72	32.10	4/4		
пеіа	35.24	31.84	4/4	4/4	33.34	32.07	4/4		
Vara	33.30	31.43	4/4		32.78	31.39	A / A		
vero	34.45	32.76	4/4	/4	33.48	31.60	4/4		
	33.65	32.40	A / A		34.49	33.36	A / A		
CHO-KI	34.70	32.83	4/4		33.89	32.40	4/4		
	32.21	31.59	4/4		33.80	32.12	A / A		
TEDIVIC	32.39	31.25	4/4		33.79	31.04	4/4		
lurkat	34.99	34.14	A/A		31.77	32.64	1/1		
Jurkat	34.80	33.50	4/4	4/4	34.30	33.81	4/4		

### 7.3.2 Device compatibility

bioteci

Link	Procedure	Acceptance Criterion	Results
See Table 17; 2	As the test can basically be performed with any qPCR cycler capable of interpreting FAM <sup>™</sup> and ROX <sup>™</sup> signals, performance of the test with these machines needs to be validated. As not all qPCR cyclers commercially available are accessible for validation, the following five devices representing block and air heating systems are tested: Rotor-Gene 6000, CFX96 touch, Mx3005P, QuantStudio5 and ABI Prism 7500. The robustness of the method was demonstrated by spiking DMEM + 5 % FBS with 99 CFU/ml of the fungi with the highest LOD <sub>95</sub> value. At least eight replicates shall be tested on each instrument.	All samples shall show a positive result.	Passed

#### Rotor-Gene 6000 (Microsart® ATMP Fungi)

Extract	C <sub>q</sub> (FAM <sup>™</sup> )		C <sub>q</sub> (R	Bocult	
Extract	Run 1	Run 2	Run 1	Run 2	Result
Positive Control	21.21	22.20	27.62	27.30	Correct
Positive Control	21.30	22.16	27.14	27.37	Correct
NTC	No Cq	No Cq	27.36	27.47	Correct
NTC	No Cq	No Cq	27.49	27.36	Correct
NEC	No Cq	No Cq	26.61	26.48	Correct
NEC	No Cq	No Cq	26.68	26.19	Correct
	28.70	35.87	23.42	26.16	Positive
	27.14	33.45	23.49	26.29	Positive
	27.16	34.66	24.20	26.01	Positive
Candida albicans	26.84	36.73	23.39	26.00	Positive
	27.27	34.01	23.41	26.26	Positive
	26.54	33.63	23.70	26.40	Positive
	27.39	34.79	24.03	26.10	Positive
	26.90	33 31	23.93	26 10	Positive







#### Mx3005p (Microsart® ATMP Fungi)

Extract	C <sub>q</sub> (FAM <sup>™</sup> )		C <sub>q</sub> (R	Posult	
Extract	Run 1	Run 2	Run 1	Run 2	Result
Positive Control	23.06	22.93	28.19	27.54	Correct
Positive Control	23.01	23.25	27.47	27.82	Correct
NTC	No Cq	No Cq	28.03	28.56	Correct
NTC	No Cq	No Cq	27.38	28.70	Correct
NEC	No Cq	No Cq	27.84	27.56	Correct
NEC	No Cq	No Cq	27.39	27.57	Correct
	29.90	32.71	28.31	27.48	Positive
	29.80	32.36	27.61	27.43	Positive
	30.24	32.87	27.37	27.89	Positive
Candida albicans	30.15	33.69	27.67	27.66	Positive
	30.40	34.19	27.40	27.53	Positive
	30.72	32.65	27.36	27.77	Positive
	32.62	33.05	27.71	27.52	Positive
	30.62	33.71	27.34	27.53	Positive

Candida albicans 99 CFU Extracts (FAM<sup>™</sup>)



Candida albicans 99 CFU Extracts (ROX<sup>™</sup>)



CFX96 (Microsart® ATMP Fungi)

Extract	C <sub>q</sub> (FAM <sup>™</sup> )		C <sub>q</sub> (R	OX™)	Pocult	
Extract	Run 1	Run 2	Run 1	Run 2	Result	
Positive Control	23.04	23.44	28.09	28.17	Correct	
Positive Control	23.15	22.99	28.29	27.45	Correct	
NTC	No Cq	No Cq	28.29	28.85	Correct	
NTC	No Cq	No Cq	28.64	28.76	Correct	
NEC	No Cq	No Cq	27.43	27.53	Correct	
NEC	No Cq	No Cq	27.45	27.80	Correct	
	30.09	33.78	27.21	27.62	Positive	
	30.03	32.30	27.30	27.97	Positive	
	30.30	33.36	27.22	28.15	Positive	
Candida albicans	30.06	32.38	27.26	27.81	Positive	
	30.46	33.16	27.30	27.75	Positive	
	30.65	33.06	27.15	27.94	Positive	
	31.99	32.39	27.21	28.05	Positive	
	30.05	33.38	27.07	27.92	Positive	



Candida albicans 99 CFU Extracts (ROX<sup>™</sup>)



#### ABI Prism (Microsart<sup>®</sup> ATMP Fungi)

Future et	C <sub>α</sub> (F	AM™)	C <sub>α</sub> (R	Decult	
Extract	Run 1	Run 2	Run 1	Run 2	Result
Positive Control	23.52	23.39	28.02	27.57	Correct
Positive Control	23.60	23.11	28.33	27.41	Correct
NTC	No Cq	No Cq	27.38	27.37	Correct
NTC	No Cq	No Cq	27.54	27.51	Correct
NEC	No Cq	No Cq	26.86	25.64	Correct
NEC	No Cq	No Cq	26.59	26.24	Correct
	29.51	31.40	26.78	26.14	Positive
	31.17	32.79	27.08	26.20	Positive
	29.61	33.57	26.87	26.41	Positive
Candida albicans	30.25	33.05	27.32	26.07	Positive
	29.11	31.04	26.74	25.76	Positive
	30.37	32.03	27.13	25.64	Positive
	29.11	32.84	26.81	25.99	Positive
	29.44	31.74	26.87	25.36	Positive





Quant Studio 5 (Microsart® ATMP Fungi)

Extract	C <sub>q</sub> (F	AM™)	C <sub>q</sub> (R	Desult	
Extract	Run 1	Run 2	Run 1	Run 2	Result
Positive Control	23.03	22.98	27.16	27.89	Correct
Positive Control	23.12	23.05	27.14	27.79	Correct
NTC	No Cq	No Cq	27.84	27.47	Correct
NTC	No Cq	No Cq	27.76	27.56	Correct
NEC	No Cq	No Cq	27.20	28.67	Correct
NEC	No Cq	No Cq	27.29	28.64	Correct
	31.73	33.31	27.39	27.54	Positive
	32.93	33.08	27.31	27.53	Positive
	31.64	34.28	27.04	27.90	Positive
Candida albicans	31.82	33.75	27.30	27.69	Positive
	31.35	35.12	27.15	27.78	Positive
	31.85	32.68	27.32	27.50	Positive
	31.16	32.74	27.38	27.50	Positive
	31.26	33.19	27.49	26.93	Positive



### 7.3.2 Detection of Free-DNA

Link	Procedure	Acceptance Criterion	Results
See Table 17; 3 and 4	In order to estimate the risk of false positive, water with and without cell suspension was spiked with 10 <sup>4</sup> ; 10 <sup>3</sup> ; 10 <sup>2</sup> or 10 GC/mI <i>Candida albicans</i> . The samples were divided in eight aliquots, extracted with Microsart <sup>®</sup> ATMP Extraction and tested with Microsart <sup>®</sup> ATMP Fungi.	n.a	Without cell lines in the sample, 0% of the free DNA is eliminated during the extraction process. With cell lines in the sample, more than 99% of the free DNA is eliminated during the extraction process.

	10⁴ G	iC/ml	10 <sup>3</sup> C	GC/ml	10 <sup>2</sup> (	GC/ml	10 0	SC/ml	0 G	C/ml
	Run 1	Run 2	Run 1	Run 2	Run 1	Run 2	Run 1	Run 2	Run 1	Run 2
Extracts	32.40	32.46	34.79	36.21	No Cq	No Cq	No Cq	No Cq	No Cq	No Cq
without cells	31.69	31.89	34.86	39.07	No Cq	No Cq	No Cq	No Cq	No Cq	No Cq
	32.87	32.29	39.69	36.18	No Cq	No Cq	No Cq	No Cq	No Cq	No Cq
	32.05	32.04	34.13	37.44	39.87	No Cq	No Cq	No Cq	No Cq	No Cq
	36.30	34.16	39.69	36.70	36.96	No Cq	No Cq	No Cq	No Cq	No Cq
	34.99	32.10	38.60	36.50	37.57	No Cq	No Cq	No Cq	No Cq	No Cq
	35.17	34.43	No Cq	38.60	No Cq	No Cq	No Cq	No Cq	No Cq	No Cq
	34.68	32.45	37.49	35.77	39.26	No Cq	No Cq	No Cq	No Cq	No Cq
	10 <sup>4</sup> GC/	ml = 10 <sup>2</sup>	10 <sup>3</sup> GC	/ml = 10	10 <sup>2</sup> GC	C/ml = 1	10 GC/	/ml = 0,1	0 G C	/PCR
	GC/	PCR	GC/	'PCR	GC	/PCR	GC	/PCR		
	Run 1	Run 2	Run 1	Run 2	Run 1	Run 2	Run 1	Run 2	Run 1	Run 2
Direct PCR	27.76	28.01	32.11	35.36	36.08	No Cq	No Cq	No Cq	No Cq	No Cq
without cells	27.92	27.77	32.43	34.17	No Cq	No Cq	No Cq	No Cq	No Cq	No Cq

After extraction of 10 GC/ml, 10  $\mu$ l extract contain less than 1GC. No free DNA was washed away during the extraction process.

S	MB minerva biolabse sartorius stedim	Product Validation Report Microsart <sup>®</sup> ATMP Fungi/Microsart® ATMP Sterile Release	Dated: 04.12.2019 Document Version: 1 Document ID: VA07.01EN Page 32 of 40
---	--	---	---

							•			
	10⁴ G	iC/ml	10 <sup>3</sup> G	iC/ml	10 <sup>2</sup> C	SC/ml	10 G	C/ml	0 G	C/ml
	Run 1	Run 2	Run 1	Run 2	Run 1	Run 2	Run 1	Run 2	Run 1	Run 2
Extracts with	31.06	29.92	35.95	34.98	No Cq	No Cq	No Cq	No Cq	No Cq	No Cq
cells	31.34	29.51	37.05	35.02	No Cq	No Cq	No Cq	No Cq	No Cq	No Cq
	31.39	30.98	38.32	32.90	No Cq	No Cq	No Cq	No Cq	No Cq	No Cq
	31.30	30.28	36.81	36.44	No Cq	No Cq	No Cq	No Cq	No Cq	No Cq
	31.75	30.15	40.28	35.61	No Cq	37.36	No Cq	No Cq	No Cq	No Cq
	31.01	30.88	36.57	37.49	No Cq	No Cq	No Cq	No Cq	No Cq	No Cq
	31.03	30.42	36.73	35.85	No Cq	No Cq	No Cq	No Cq	No Cq	No Cq
	31.21	30.58	36.42	34.09	No Cq	No Cq	No Cq	No Cq	No Cq	No Cq
$10^4 \text{GC/ml} = 10^2$		10 <sup>3</sup> GC/ml = 10		$10^2 \text{GC/mI} = 1$		10 GC/ml = 0,1		0 GC/PCR		
	GC/PCR		GC/PCR		GC/PCR		GC/PCR			
	Run 1	Run 2	Run 1	Run 2	Run 1	Run 2	Run 1	Run 2	Run 1	Run 2
Direct PCR	26.42	26.01	32.27	30.38	37.28	33.94	No Cq	No Cq	No Cq	No Cq
without cells	26.22	25.94	32.49	30.94	38.14	35.45	No Ca	No Ca	No Ca	No Ca

After extraction 100 GC/ml, 10  $\mu l$  extract contain less than 1GC. Thus, more than 90% free DNA was washed away during the extraction process.

### 7.3.3 False positive rate

Link	Procedure	Acceptance Criterion	Results
See Table 2 See Table 17; 5	Cell culture Media without spike were extracted with Microsart® ATMP Extraction and tested with Microsart® ATMP Fungi. 12 independent experiments were performed for DMEM + 5%FBS, each with eight replicates. For other culture media, one experiment was performed, with eight replicates.	n.a	All the run conducted with Microsart <sup>®</sup> ATMP Extraction and Microsart <sup>®</sup> ATMP Fungi were valid indicating that none of those media affect the performance of the kit.

	Negative Results	% negative results
	8/8	
	8/8	
	8/8	
	8/8	
	8/8	
DMEM +	8/8	1009/
5% FBS	8/8	100%
	8/8	
	8/8	
	8/8	
	8/8	
	8/8	

Dated: 04.12.2019 Document Version: 1 Document ID: VA07.01EN Page 33 of 40

	Negative Results	ROX™	% negative results
DMEM	8/8	8/8 Correct	100%
Fetal bovine serum (FBS)	8/8	8/8 Correct	100%
DMEM high Glucose, GlutaMAX	8/8	8/8 Correct	100%
DMEM w/o Na-Pyruvat mit stable Glutamin	8/8	8/8 Correct	100%
RPMI 1640	8/8	8/8 Correct	100%
MEM (1)	8/8	8/8 Correct	100%
MEM (2)	8/8	8/8 Correct	100%
KnockOut DMEM	8/8	8/8 Correct	100%
DMEM/F-12 GlutaMAX	8/8	8/8 Correct	100%
Opti-MEM Reduced Serum GlutaMAX	8/8	8/8 Correct	100%
McCoys 5A Medium	8/8	8/8 Correct	100%
Leibovitz L-15 Medium	8/8	8/8 Correct	100%
Chrondrocyte Differentiation Medium	8/8	8/8 Correct	100%
Human Osteoblast Differentiation Medium	8/8	8/8 Correct	100%
ChondroMAX Differentiation Medium	8/8	8/8 Correct	100%
Tahara Lympho One + HS	8/8	8/8 Correct	100%
RPMI, penicillin/Streptomycin, Glutamax, 5% FBS	8/8	8/8 Correct	100%

### 8 Conclusion

Microsart<sup>®</sup> ATMP Fungi and the Fungi SR mix from Microsart<sup>®</sup> ATMP Sterile Release were intensively validated in compliance with the designed validation protocol. The validation protocol reflects the method itself and variations expected by the diversity of samples from different customers during QC testing in the manufacturing process of ATMP samples. Microsart<sup>®</sup> ATMP Fungi should be applied for fungi detection for any kind of sample material occurring in the manufacturing process of ATMP.

Microsart<sup>®</sup> ATMP Fungi and its derivate product Microsart<sup>®</sup> ATMP Sterile Release were designed as state-of-the-art new product for the detection of fungi contaminations in ATMP products. The product validation has been conducted according to the European Pharmacopoeia 2.6.1 and 2.6.27 regulations for sterility testing and microbiological control of cellular products such as ATMP.

Specificity of the tested fungi revealed a detection limit  $(LOD_{95})$  comprised between 10 and 99 CFU/mI and a great sensitivity of the PCR system, able to detect as little as 10 GC/PCR for various species.

*In silico* sequence alignments analysis demonstrated that Microsart<sup>®</sup> ATMP Fungi and Microsart<sup>®</sup> ATMP Sterile Release can detect > 37 % of fungi. This feature greatly increase the chances to detect any kind of fungal contamination, including some species difficult to detect with the classical culture method. A direct comparison with the culture method recommended by EP 2.6.1 was performed and showed 100% of similarities between the results obtained through both methods.

As robustness is a key issue in evaluating the characteristics of a product, the kit has been validated with various relevant samples, with different cyclers and by different experimenter in different laboratory environments. All collected results are consistent and confirm the accuracy and reproducibility of Microsart<sup>®</sup> ATMP Fungi and of Microsart<sup>®</sup> ATMP Sterile Release in those diverse surroundings for the detection of fungal DNA.

It was shown that the product Microsart<sup>®</sup> ATMP Fungi and Microsart<sup>®</sup> ATMP Sterile Release offer an appropriate replacement solution to the culture method described in EP 2.6.1 and EP 2.6.27 and can be safely used to detect the presence of fungal contamination in cell culture derived samples including ATMPs.

### 9 **Reference Documents**

- 1. European Pharmacopoeia 8th edition, Strasbourg, FR; European Directorate for the Quality of Medicines; 2014, 5.1.6
- 2. European Pharmacopoeia 8th edition, Strasbourg, FR; European Directorate for the Quality of Medicines; 2014; 2.6.21 Nucleic Acid Amplification Techniques
- 3. US Pharmacopoeial Convention (USP). USP 38/NF 33 <1223>, 2015

# 10 Appendix

		L	abor LS		
Bericht über Resultate der Prüfung auf Sterilität					
Titel:	Bericht zur Prüfur samples"	Bericht zur Prüfung auf Sterilität an "Cell culture medium samples"			
LS-Nr.:	191017-0115-001 k	191017-0115-001 bis 016			
Probe/Produkt:	Cell culture medium 16 Gebinde mit jev	Cell culture medium sample 16 Gebinde mit jeweils 1 ml			
Standort:	Labor LS 97708 Bad Bocklet Deutschland	Labor LS 97708 Bad Bocklet – Großenbrach Deutschland			
Kunde/Sponsor:	Sartorius Stedim Bi August-Spindler-St 37079 Göttingen Deutschland	Sartorius Stedim Biotech GmbH August-Spindler-Straße 11 37079 Göttingen Deutschland			
Beginn der Untersuchungen:	17.10.19	Ende der Untersuchung:	04.11.19		
Auftrag vom:	17.10.19	Probeneingang am:	17.10.19		

Dated: 04.12.2019 Document Version: 1 Document ID: VA07.01EN Page 37 of 40

# Labor LS

#### 1. Prüfungsdurchführung

#### 1.1 Prüfung auf Sterilität

Die Prüfungen wurden am 17. Oktober 2019 mittels Direktbeschickung unter einer qualifizierten Sicherheitswerkbank (LS SWB 024) durchgeführt.

Hierbei wurde jeweils der Gesamtinhalt pro Gebinde aseptisch in einen 400 ml Kolben Nährmedium überführt. Gemäß Kundenvorgaben wurden die Proben mit der Bezeichnung "a" in 400 ml Thioglykolat-Bouillon mit Enthemmerzusatz (Charge 66-0909190952) überführt. Die Proben mit der Bezeichnung "b" wurden in 400 ml Caso-Bouillon (Charge 19-0909190952) mit Enthemmerzusatz überführt.

#### 1.2 Inkubation

Nach der Prüfungsdurchführung wurden die Testansätze bei 22,5  $\pm$  2,5 °C (Caso-Bouillon, KL 018) bzw. 32,5  $\pm$  2,5 °C (Thioglykolat-Bouillon, KL 017) in qualifizierten Klimakammer mit kontinuierlicher Temperaturaufzeichnung für mind. 14 Tage inkubiert.

#### 1.3 Auswertung

Alle Testansätze wurden arbeitstäglich auf makroskopisch sichtbares Wachstum überprüft. Sobald Trübung bzw. makroskopisch sichtbares Wachstum detektiert wurde, wurde die Inkubation unterbrochen. Je ein Aliquot des betroffenen Flüssignährmediums wurde auf 2 Platten Columbia-Blut-Agar und einer SDA-(Sabouraud-Dextrose-Agar)-Platte ausplattiert. Je eine Blut-Agar-Platte wurde aerob, die zweite anaerob bei 30 - 35°C inkubiert. Die SDA-Platte bei 28,5 – 31,5°C. Nachdem Keimwachstum auf den Platten nachweisbar war, wurde mittels VITEK®MS bzw. mikroskopisch (bei Schimmelpilzen) identifiziert.

Die Nährmedienansätze, bei welchen kein makroskopisch sichtbares Wachstum erkennbar war, wurden bis zum Ende der 14-tägigen Inkubationszeit inkubiert. Die Endauswertung erfolgte im 4-Augen-Prinzip.

Bericht über Resultate der Prüfung auf Sterilität Produktbezeichnung: Cell culture medium sample LS-Nr.: 191017-0115-001 bis 016

Version: 01 Seite: 2 von 5

Dated: 04.12.2019 Document Version: 1 Document ID: VA07.01EN Page 38 of 40



#### 2. Ergebnisse

Alle Ergebnisse der visuellen Auswertung sowie der Identifizierung sind der folgenden Tabelle zu entnehmen:

Tabelle 1: Übersicht Ergebnisse

LS-Nr.:	Bezeichnung	Makroskopisch sichtbares Wachstum am Tag	Ergebnis <sup>1)</sup>	Nährmedien	Ergebnis Identifizierung
191017-0115-001	1 a	-	negativ	Thio +	-
191017-0115-002	2 a	7	negativ <sup>2)</sup>	Thio +	-
191017-0115-002	3 a	7	positiv	Thio +	Candida albicans
191017-0115-004	4 a	7	positiv	Thio +	Candida albicans
191017-0115-005	5 a	7	negativ <sup>2)</sup>	Thio +	-
191017-0115-006	6 a	8	positiv	Thio +	Aspergillus brasiliensis
191017-0115-007	7 a	7	positiv	Thio +	Aspergillus brasiliensis
191017-0115-008	8 a	7	positiv	Thio +	Aspergillus brasiliensis
191017-0115-009	1 b	-	negativ	Caso +	-
191017-0115-010	2 b	-	negativ	Caso +	-
191017-0115-011	3 b	7	positiv	Caso +	Candida albicans
191017-0115-012	4 b	7	positiv	Caso +	Candida albicans
191017-0115-013	5 b	-	negativ	Caso +	-
191017-0115-014	6 b	11	positiv	Caso +	Aspergilllus brasiliensis
191017-0115-015	7 b	7	positiv	Caso +	Aspergillus brasiliensis
191017-0115-016	8 b	7	positiv	Caso +	Aspergillus brasiliensis

<sup>1)</sup> negativ: kein Keimwachstum, positiv: Keimwachstum <sup>2)</sup> Testabbruch nach 7 Tagen. Anschließend kein Keimwachstum nachweisbar (siehe Abweichung A6886)

Bericht über Resultate der Prüfung auf Sterilität Produktbezeichnung: Cell culture medium sample LS-Nr.: 191017-0115-001 bis 016

Version: 01 Seite: 3 von 5

Dated: 04.12.2019 Document Version: 1 Document ID: VA07.01EN Page 39 of 40



Die Zuordnung der jeweiligen LS-Nummer der Sterilitätsprüfung zur entsprechenden LS-Nummer der Keimidentifizierung ist in folgender Tabelle zusammengefasst:

Tabelle 2: Zuordnung LS-Nummer Sterilitätsprüfung und Keimidentifizierung

LS-Nr. Prüfung auf Sterilität	LS-Nr. Identifizierung
191017-0115-002	191017-0115-017
191017-0115-003	191017-0115-018
191017-0115-004	191017-0115-019
191017-0115-005	191017-0115-020
191017-0115-006	191017-0115-027
191017-0115-007	191017-0115-021
191017-0115-008	191017-0115-022
191017-0115-011	191017-0115-023
191017-0115-012	191017-0115-024
191017-0115-014	191017-0115-028
191017-0115-015	191017-0115-025
191017-0115-016	191017-0115-026

#### 3. Zusammenfassung und Bewertung

In 10 der 16 Prüfmuster wurde mikrobiologisches Wachstum detektiert. 4 Prüfansätze zeigten kein makroskopisch sichtbares Wachstum und entsprechen nach 14 Tagen Inkubation den Akzeptanzkriterien des Steriltests gemäß Ph. Eur., Kapitel 2.6.1.

Bei 2 Prüfansätzen wurde nach 7 Tagen makroskopisch sichtbare Veränderung des Mediums detektiert. Nach Anlegen von Subkulturen auf festem Nährmedium war kein Keimwachstum detektierbar. Eine Abweichungsmeldung wurde gestartet (Vorgangsnummer A6888); im Zuge der Ursachenanalyse wurden Sequenzierungen zum Nachweis bakterieller DNA bzw. der DNA von Hefen oder Schimmelpilzen eingeleitet. In keinem Versuch war der Nachweis von DNA möglich. Die beiden Testansätze (LS-Nr. 191017-0115-002 und 191017-0115-005) zeigten bei wiederholter visueller Prüfung kein makroskopisch sichtbares Wachstum.

 Bericht über Resultate der Prüfung auf Sterilität

 Produktbezeichnung: Cell culture medium sample

 LS-Nr.:
 191017-0115-001 bis 016

Version: 01 Seite: 4 von 5



Ende des Dokuments

Bericht über Resultate der Prüfung auf Sterilität Produktbezeichnung: Cell culture medium sample LS-Nr.: 191017-0115-001 bis 016

Version: 01 Seite: 5 von 5